Methods of treating glomerulonephritis associated with IGA nephropathy for TACI-immunoglobulin fusion proteins
US9346878B2 · kind B2 · utility
3Cited by
9References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 15, 2014 |
| Grant date | May 24, 2016 |
| Priority date | — |
| Expiry date | Jul 15, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.